Acetaminophen works via the brain’s endocannabinoid system to both reduce pain and induce changes that are beneficial for ...
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 ...
In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia ...
Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a ...
The tiny fruit fly could have a mighty impact on identifying optimal treatments for people with alcohol use disorder. A new ...
BI765845 is an experimental drug developed by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ...
Clinical Trials Arena on MSN
Trials to watch: Three major catalysts in Alzheimer’s disease
While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms ...
DelveInsight’s “Atopic Dermatitis Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ ...
Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and associated metabolic diseases.It is currently ...
Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3 ...
Understanding how drugs interact with their molecular targets at the atomic level is central to modern drug discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback